Metabolic · In Clinical Trials
Apraglutide
No lawful US pathway
01 · Overview
Apraglutide is a long-acting glucagon-like peptide-2 (GLP-2) receptor agonist given once weekly by subcutaneous injection, designed to promote intestinal adaptation and improve absorption in patients with short bowel syndrome (PMID 42692160). The peptide analogue is related to native GLP-2 but modified to extend its duration of action.
By binding to GLP-2 receptors in the intestine, it supports growth of the intestinal lining and adaptive intestinal function.
02 · Research summary & key findings
An earlier open-label phase 1/2 metabolic balance trial reported improved intestinal fluid and energy absorption in patients with short bowel syndrome (PMID 35233802). In the phase 3 STARS trial in 163 patients with SBS and intestinal failure, once-weekly apraglutide reduced weekly parenteral support volume by 25.5 percent versus 12.5 percent with placebo at week 24, with a larger effect in patients with a stoma (PMID 42692160). In patients with colon-in-continuity, differences in days off parenteral support and enteral autonomy at week 48 were not statistically significant (PMID 42692160).
03 · Regulatory status
Apraglutide is currently undergoing clinical trials. It is not yet FDA-approved and is available only through clinical research settings or investigational protocols.
No lawful pathway today
Apraglutide is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so we do not sell it and will not book a consultation for it. That can change: in 2026 FDA began reviewing several peptides for compounding. If you are working on the goal it is studied for, a licensed clinician can tell you what is lawfully available, which may be something else.
See the 13 FDA-approved compounds in Metabolic
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Looking for a lawful, clinician-prescribed option for metabolic health and weight?
Apraglutide is still in clinical trials, is not FDA-approved, and has no lawful US compounding pathway, so we do not offer it and no clinician we work with will prescribe it. Products sold online as “research chemicals” are not made or tested to the standards required of medicines. If you are working on metabolic health and weight, a licensed clinician can tell you at a free consultation whether an FDA-approved or lawfully compounded treatment fits you, or whether nothing does.
Explore lawful options (free intake)About 3 minutes. If a protocol is prescribed through our provider, we earn 10% of the sale. See the receipts.
04 · Administration routes
- Subcutaneous injection
References
- [1]Apraglutide, a novel once-weekly glucagon-like peptide-2 analog, improves intestinal fluid and energy absorption in patients with short bowel syndrome: An open-label phase 1 and 2 metabolic balance trial JPEN J Parenter Enteral Nutr, 2022. PMID 35233802
- [2]STARS Phase 3 Trial: Once-Weekly Apraglutide Reduces Parenteral Support in Short Bowel Syndrome-Intestinal Failure Clin Gastroenterol Hepatol, 2026. PMID 42692160
Primary literature
- PubMed: "Apraglutide"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Apraglutide"
Registered interventional and observational studies, including status and phase.
- PubChem: "Apraglutide"
Chemical structure, molecular properties, and bioactivity data.
Related peptides in Metabolic
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.